Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
115 hedge funds and large institutions have $828M invested in Epizyme, Inc in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 31 closing their positions.
1,859% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $139K
14% less funds holding
Funds holding: 134 → 115 (-19)
17% less capital invested
Capital invested by funds: $1B → $828M (-$174M)
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
61% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$20.3M |
| 2 |
Primecap Management
Pasadena,
California
|
+$15.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.26M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$6.24M |
| 5 |
Millennium Management
New York
|
+$5.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$9.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.24M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.63M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$7.32M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.82M |
EPZM Hedge Fund Activity: Q3 2019 in Review
115 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2019, worth a combined $828M — down 17% from $1B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of EPZM and 12 opened new positions — a net loss of 19 holders — while 44 trimmed existing stakes and 31 added.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $20.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.9M.
- 115 institutional investors held Epizyme, Inc (EPZM) as of Q3 2019, down from 134 in Q2 2019.
- Funds reported $828M of Epizyme, Inc stock for Q3 2019, down 17% quarter-over-quarter.
- 12 funds opened new Epizyme, Inc positions in Q3 2019 and 31 closed out, a net change of -19 holders.
- The largest Epizyme, Inc buyer in Q3 2019 was Loomis, Sayles & Company, an estimated $20.3M added.
- The largest Epizyme, Inc seller in Q3 2019 was Consonance Capital Management, an estimated $9.9M sold.
Based on aggregated 13F filings for Q3 2019.